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Abstract
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Background/Aims—Current staging guidelines for small intestinal neuroendocrine tumors (SINETs) differentiate between the presence (N1) and absence (N0) of lymph node (LN) metastases.
However, the prognostic significance of the extent of LN involvement remains unknown. In this
study, we used data from a population-based cancer registry to examine whether involvement of a
higher number of LNs is associated with worse survival.
Methods—We used the Surveillance, Epidemiology and End Results (SEER) database to
identify patients with histologically confirmed, surgically resected SI-NETS diagnosed between
1988 and 2010. Patients were classified into three groups by the lymph node ratio (number of
positive lymph nodes/number of total lymph nodes examined, LNR): ≤0.20, >0.20–0.5, and >0.5.
We used the Kaplan Meier method and Cox models to assess NET cancer-specific survival
differences (up to 10 years from diagnosis) according to LNR status.

Author Manuscript

Results—We identified 2,984 surgically resected patients with stage IIIb (N1, M0) SI-NETs
with detailed LN data. More than half of NETs were located in the ileum. Higher LNR was
significantly associated with worse NET cancer-specific survival (p<0.0001). Ten-year NETspecific survival was 85%, 77%, and 74% for patients in the ≤0.2, >0.2–0.5, and >0.5 LNR
groups, respectively. In stratified analyses, higher LNR groups had worse survival only in early
tumor (T1, T2) disease (p<0.0001).
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Conclusions—Extent of LN involvement provides independent prognostic information in
patients with LN positive SI-NETs. This information may be used to identify patients at high risk
of recurrence and inform decisions about use of adjuvant therapy.
Keywords
small intestine; neuroendocrine tumor; carcinoid; staging; lymph node

Introduction

Author Manuscript

The incidence of small intestinal neuroendocrine tumors (SI-NETs) has tripled over the last
several decades, likely due to increased performance of imaging and endoscopic procedures.
[1, 2] The clinical course may vary from slowly progressive to highly aggressive disease
with heterogeneous patient outcomes. This variability poses significant challenges in
treatment and medical decision-making. Therefore, accurate staging is critical in
management of SI-NET patients; it informs treatment selection and discussions about
prognosis and guides eligibility for clinical trials.

Author Manuscript

In SI-NET patients, the presence of lymph node (LN) involvement is associated with worse
survival and may have important treatment implications.[3] In both the American Joint
Committee on Cancer (AJCC) and European Neuroendocrine Tumor Society (ENETS)
staging classifications, SI-NETs are classified as N0 or N1 disease based on absence or
presence of lymph node metastases, respectively (Appendix).[4, 5] Ten-year cancer-specific
survival is 87% for N0 disease, as compared to 77% for N1 cases.[3] However, there is
considerable survival heterogeneity even among NET patients with N1 disease.[6, 7] While
not considered in the NET classification, the extent of LN involvement (i.e., the number of
positive regional nodes) is an established predictor of survival in other cancers.[8–15]
However, it remains unknown whether this potential prognostic factor provides additional
information beyond tumor (T) and node (N) status in SI-NETs.
In this study, we used the National Cancer Institute’s Surveillance, Epidemiology and End
Results (SEER) cancer registry to assess the prognostic impact of the extent of LN
involvement among patients with SI-NETs. We hypothesized that more extensive LN
involvement will accurately discriminate patients with worse disease-specific survival.

Materials and Methods
Study Population

Author Manuscript

We identified patients with SI-NETs (site codes: C170–173; 178, 179; histological codes:
8240–8250, 8150–8156, and 9091) diagnosed between 1988 and 2010 from the SEER
database, a national cancer registry that collects information from incident malignancies
across several areas of the United States.[16] We included all patients 18 years of age or
older with pathologically confirmed SI-NETs and without a history of other cancers. We
excluded cases diagnosed at autopsy or on death certificate or cancers with incomplete
staging information. We further limited the cohort to patients with surgically resected, stage
IIIb disease (Any T, N1, M0: tumor of any size and depth [T1–T4], no regional lymph node
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metastasis [N0], no distant metastasis [M0]).[5] We also identified all resected stage I–IIIa
patients who were used as a reference population.
Demographic data such as gender, age, race/ethnicity and marital status were obtained from
SEER. T, N and M status was determined based on detailed data provided by SEER on
primary tumor size, depth of invasion, local extension, lymph node involvement, and
presence/absence of distant metastases. Using these information, cancer stage was assigned
according to ENETS and AJCC staging criteria.[4, 5] SEER also includes data regarding use
of surgery as part of the primary cancer treatment. We categorized type of resection as: 1)
local resection (surgical code 20); 2) partial or simple resection (surgical code 30); 3) total
resection (surgical code 40); or 4) debulking surgery (surgical codes 50–60).

Author Manuscript

The number of positive LNs can be used as a marker for extent of LN involvement.
However, this feature is confounded by the number of LNs removed during surgery.[17–20]
This is particularly problematic as no standards exist about the number of LNs that should
be removed during SI-NET operations. To address this issue, the lymph node ratio (LNR),
defined as the ratio between the number of positive nodes and the number of LNs removed
during surgical resection, has been used to in other gastrointestinal cancers.[17, 21–23]
Based on cutoffs used in prior studies and the distribution of LNR in the study cohort, we
classified patients into three LNR groups: ≤0.20, >0.2–0.5, and >0.5.

Author Manuscript

Survival time was calculated as the period from date of diagnosis until death or last followup (December 31, 2010). We used SI-NET-specific survival as the main study outcome in
order to evaluate differences in cancer prognosis according to LNR categories. Cause of
death was determined using SEER data abstracted from death certificates. Individuals who
were alive at last follow-up or who died from non-NET causes were treated as censored
observations. This study was exempt from IRB review.
Statistical Analysis

Author Manuscript

We used the t-test and chi square test to compare the distribution of patients’ characteristics
such as age, sex, race/ethnicity, marital status, tumor site, T status, and type of surgical
resection according to LNR group. We then constructed Kaplan-Meier curves to estimate SINET-specific survival for each LNR category; the log-rank test was used to compare
survival between groups. Survival curves were plotted up to ten years after diagnosis to
assess long-term outcomes of these relatively slowly progressive tumors while avoiding
estimating survival curves with small number of cases. We repeated the analyses within
anatomic site strata to assess the association of LNR with SI-survival among jejunoileaI vs.
duodenal cancers. We also performed stratified analyses by T status. We used Cox
proportional hazards models to evaluate the association between LNR groups and NETspecific survival after adjusting for age, sex, race/ethnicity, marital status, T status, and type
of surgical resection. All analyses were performed using SAS version 9.3 (SAS Institute
Inc., Cary, NC, USA) using two-sided p values.
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Results
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From SEER, we identified 11,464 SI-NETs diagnosed between 1988 and 2010. We
excluded 2,658 (23%) patients who had other primary cancers and 1,283 (11%) who had
incomplete staging information (Figure 1). From these, we selected 2,984 surgically resected
patients with stage IIIb disease who underwent surgical resection and had detailed lymph
node data. As a control, we also included data from 860 resected patients with N0 disease.
More than half (60%) of stage IIIb cases were located in the ileum. The median number of
lymph nodes removed was 10 (interquartile range, 11). Approximately 30%, 39%, and 31%
of the cohort had a LNR of ≤0.2, >0.2–0.5, and >0.5, respectively. Demographic
characteristics of study patients according to LNR group, as well as the reference
population, are shown in Table 1. Patients in the highest LNR group were older (p<0.0001)
and male (p=0.005). The groups were similar with respect to race/ethnicity (p=0.57) and
marital status (p=0.28). However, cancers in the jejunum (p<0.0001) and with advanced T
(T3 or T4) status (p<0.0001) were more common in the highest LNR category. Finally,
patients in the highest LNR group were more likely to have local and partial surgical
resections rather than total resection or debulking surgery (p<0.0001).
Kaplan-Meier analysis showed progressively worse disease-specific survival with higher
LNRs (p<0.0001, Figure 2). Ten-year survival was 85% (95% confidence interval [CI]: 81–
89%), 77% (95% CI: 73–80%), and 74% (95% CI: 69–78%) for patients in the ≤0.2, 0.21–
0.5, and >0.5 LNR groups, respectively. As a comparison, 10-year SI-NET specific survival
for N0 disease was 85% (95% CI: 81–89%).

Author Manuscript

Stratified analyses by T status demonstrated progressively worse survival with higher LNR
in patients with early T (T1, T2; p<0.0001) but not among those with late T status (T3,
p=0.24; T4, p=0.40) (Figure 3). Among those with early disease, patients with LNR≤0.2 had
10-year survival of 94.2% (95%CI: 90–98%), as compared to 91.8% (95%CI: 87–96%) for
LNR of >0.2–0.5 and 82.5% (95% CI: 74–91%) for LNR>0.5. Conversely, there was no
significant association between LNR and survival in patients with T3 (p=0.24) or T4
(p=0.40) disease. These findings persisted in stratified analyses among patients with
jejunoileal or duodenal disease.

Author Manuscript

Cox analysis also showed a differential effect of LNR status on disease-specific survival,
according to T status (i.e., a significant interaction between LNR and T status; Table 2). In
patients with early T (T1, T2) status, the hazards of death was 1.6 (95%CI: 0.72–3.56), 2.29
(95%CI: 1.10–4.78), 4.52 (95%CI: 2.24–9.12) for those with LNR≤0.2, >0.2–0.5, and >0.5,
as compared to patients with N0 disease. Conversely, in patients with T3 status, diseasespecific survival in LNR≤0.2 (HR 0.78, 95%CI: 0.18–3.28), >0.2–0.5 (HR 0.91, 95%CI:
0.22–3.74), or >0.5 (HR 1.00; 95%CI: 0.25–4.07) were not significantly different compared
to those with N0 disease. Similarly, disease--specific mortality among T4 patients with
LNR≤0.2 (HR 0.71, 95%CI: 0.16–3.22), LNR >0.2–0.5 (HR 0.98, 95%CI: 0.23–4.16), and
LNR >0.5 (HR 0.97, 95%CI: 0.23–4.09) was not significantly different as compared to
patients with N0 disease. These results persisted after adjusting for number of lymph nodes
removed; there was no significant association between LNR and the number of lymph nodes
examined.
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Discussion
Accurate staging of NETs is critical for patient management and research. While current
ENETS/AJCC classifications help in identification of poor prognostic groups, there is still
considerable heterogeneity in the outcomes of patients within specific categories. In this
study, we found that the LNR, a readily available measure of the extent of regional LN
involvement, was an independent predictor of survival among patient with locoregional SINETs. A revised staging system which incorporates this feature may improve
prognostication of patients with node-positive SI-NETs.

Author Manuscript

Our findings regarding the importance of the LNR are consistent with studies in other GI
cancers. Greenstein et al demonstrated in 838 node-positive esophageal carcinoma patients
that higher LNR was independently associated with worse outcomes.[24] Similarly, other
studies have demonstrated that LNR is an independent prognostic predictor in patients with
node-positive gastric and colon cancer.[17] Our study extends these findings to SI-NET
patients, demonstrating that LNR can be used to differentiate outcomes, beyond that of the
existing TNM-based classification. Higher LNR disease may reflect tumors with more
aggressive biology or extensive disease.

Author Manuscript

Existing clinical, biochemical, and pathologic markers aid clinicians in assessment of extent
of disease and response to therapy. Clinical factors such as the presence of carcinoid
syndrome or carcinoid heart disease predict poor prognosis but are only present in a small
subset of patients with metastatic disease; thus, limiting its utility. Chromogranin A is the
most frequently used tumor marker in NETs, but is falsely elevated by near-ubiquitous use
of proton pump inhibitors.[25–30] Tumor grade (as measured by mitotic and Ki67 indices)
is incorporated into the ENETS and AJCC classifications and has been shown in multiple
studies to predict prognosis, but is not performed routinely outside of tertiary hospitals or
specialty NET centers.[4, 5] Moreover, lack of standardization of assays and reporting
further hinders use in clinical practice. Thus, there is a need for additional prognostic factors
to provide information to patients and clinicians.
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While LNR is only available in patients who undergo surgical resection, it is a simple and
readily available marker. It is routinely reported as part of pathological staging and could be
incorporated in revised classifications without additional cost. Importantly, routine use of
the LNR can have direct clinical implications. For example, patients with high LNR may
require more aggressive monitoring and treatment. Thus, future trials should assess the
potential benefit of adjuvant therapy for these high-risk individuals. Additionally, LNR
information may help in selecting homogenous populations of SI-NET patients to be
enrolled in clinical trials. Accurate data may also help patient-provider discussions about
prognosis and facilitate informed patient decision making.
The major strengths of our study were our large sample of SI-NETs and availability of longterm survival data. Both of these features enabled us to detect differences in outcomes
among patients with nodal disease, while adjusting for established TNM-based prognostic
factors. Another strength of this analysis was the use of a population-based sample thus
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limiting the impact of referral bias. Finally, the detailed LN data available from SEER
enabled us to study nodal features that are not typically available in other cancer registries.
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The major limitation of this study was the lack of available tumor grade information. Both
the mitotic and Ki67 labeling index are recognized prognostic factors incorporated into the
ENETS and AJCC classifications.[4, 5] Thus, we were not able to assess whether the LNR
is an independent predictor of prognosis after controlling for tumor grade. However, most
SI-NETs demonstrate lower proliferation, suggesting that tumor grade would not be a major
confounder. Moreover, the data required to calculate LNR is free, while tumor grade poses
additional costs. Another limitation was that cause of death was abstracted from death
certificates, thereby introducing potential for misclassification. However, NET-specific
survival rates in SEER are consistent with those reported in institutional-based studies with
more detailed information about cause of death.[6] Finally, the accuracy of LNR may be less
reliable with smaller number of removed lymph nodes; we were also unable to account for
lymph node involvement at specific locations (eg. mesentery), as this data is not recorded in
the SEER registry.
In summary, our findings suggest that LNR independently predicts prognosis and can further
discriminate outcomes in patients with node-positive SI-NETs. More detailed LN data could
be incorporated into the current staging system to allow for better assessment of prognosis in
this patient population. In addition, these data suggest that patients with high LNR are at risk
for worse outcomes and may be considered for more aggressive postoperative therapy.
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Appendix American Joint Committee on Cancer and European
Neuroendocrine Tumor Society Staging and Grading Classification for
Small Intestinal Neuroendocrine Tumors
Primary Tumor (T)
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Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Tumor invades lamina propria or submucosa and size<=1cm
T2: Tumor invades muscularis propria or size>1cm
T3: Tumor invades through muscularis propria into subserosa or into nonperitonealized tissue
T4: Tumor invades visceral peritoneum (serosa) or other organs or structures
Regional Lymph Nodes (N)
Nx: Regional lymph nodes cannot be assessed
N0: No regional lymph node metastasis
N1: Regional lymph node metastasis
Distant Metastasis (M)
Mx

Author Manuscript

M0: No distant metastasis
M1: Distant metastasis
Stage
Stage I

T1

N0

M0

Stage IIa

T2

N0

M0

IIb

T3

N0

M0

T4

M0

M0

IIIb

Any T

N1

M0

Stage IV

Any T

Any N

M1

Stage IIIa

Author Manuscript

Grade

Mitotic Index (per 10 HPF)

Ki-67 Index (%)

G1

<2

<3%

G2

2–20

3–20%

G3

>20

>20%

HPF: High Powered Field
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Figure 1.

Flow diagram for SI-NET patients included in the study.
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Figure 2.

Disease-specific survival stratified by LNR status. Disease-specific survival was
progressively worse with increasing LNR (p<0.0001). There was overlap of survival in
patients with N0 and lowest LNR status.
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Figure 3.
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Figure 3A. In patients with early T (T1, and T2), disease-specific survival was progressively
worse with increasing LNR (p<0.0001).
Figure 3B. In patients with T3 status, higher LNR was not associated with worse diseasespecific survival.
Figure 3C. In patients with T4 status, higher LNR was not associated with worse diseasespecific survival.
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114 (13.3)
53 (6.2)
29 (3.4)

Black

Hispanic

Other

510 (59.3)
83 (9.6)
107 (12.4)
41 (4.8)

Married

Separated/Divorced

Widowed

Unknown
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51 (5.9)
457 (53.1)
8 (0.9)
8 (0.9)
204 (23.7)

Jejunum

Ileum

Meckel’s diverticulum

Overlapping lesion

Small intestine, NOS

191 (22.2)
256 (29.8)
282 (32.8)

1

2

3

T Status, No (%)

132 (15.3)

Duodenum

Cancer Site, No (%)

119 (13.8)

Single

Marital Status, No (%)

664 (77.2)

434 (50.5)

61.2 (14.3)

N0 (n=860)

White

Race/Ethnicity, No (%)

Male, No (%)

Age, years, mean (SD)

Characteristic

417 (48.2)

221 (25.6)

84 (9.7)

176 (19.8)

11 (1.2)

1 (0.1)

625 (70.4)

36 (4.0)

39 (4.4)

27 (3.0)

93 (10.5)

58 (6.5)

601 (67.7)

109 (12.3)

23 (2.6)

48 (5.4)

98 (11.0)

719 (81.0)

454 (51.1)

59.6 (12.5)

≤0.20 (n=888)

598 (53.3)

223 (19.9)

38 (3.4)

329 (28.2)

12 (1.0)

6 (0.5)

703 (60.2)

64 (5.5)

54 (4.6)

42 (3.6)

143 (12.2)

109 (9.3)

726 (62.2)

148 (12.7)

24 (2.0)

69 (5.9)

129 (11.9)

936 (80.1)

583 (49.9)

61.7 (12.9)

0.21–0.5 (n=1,168)

Lymph Node Ratio

Author Manuscript

Demographic Characteristics of Study Subjects (N= 2,984)

492 (54.9)

132 (14.7)

11 (1.2)

339 (36.5)

18 (1.9)

5 (0.5)

457 (49.3)

75 (8.1)

34 (3.7)

34 (3.7)

102 (11.0)

73 (7.9)

618 (66.6)

101 (10.9)

19 (2.1)

61 (6.6)

124 (13.4)

724 (78.0)

527 (56.8)

62.6 (12.4)

>0.5 (n=928)

<0.0001

<0.0001

0.28

0.57

0.005

<0.0001

P-value*

Author Manuscript
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139 (16.2)

160 (18.0)

189 (21.3)

518 (58.3)

21 (2.4)

143 (16.5)

210 (18.0)

238 (20.4)

687 (58.8)

33 (2.8)

263 (23.4)

0.21–0.5 (n=1,168)

P values reflect comparisons of the three LNR groups.

*

SD: standard deviation; No: number; NOS: Not otherwise specified; T: Tumor

142 (16.5)

Debulking surgery

527 (61.3)

Total resection

52 (6.0)

Partial/simple resection

131 (15.2)

Local resection

Surgery, No (%)

4

≤0.20 (n=888)

Author Manuscript
Lymph Node Ratio

108 (11.6)

164 (17.7)

613 (66.1)

43 (4.6)

261 (29.1)

>0.5 (n=928)

<0.0001

P-value*

Author Manuscript

N0 (n=860)

Author Manuscript

Characteristic
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Table 2

Author Manuscript

Influence of LNR Status on Risk of Disease-specific Mortality
Disease Status

N

Reference

Hazard Ratio

95% Confidence Interval

T1T2, LNR≤0.2

305

T1T2, N0

1.60

0.72–3.56

T1T2, 0.2<LNR≤0.5

261

T1T2, N0

2.29

1.10–4.78

T1T2, LNR>0.5

143

T1T2, N0

4.52

2.24–9.12

T3, LNR≤0.2

417

T3, N0

0.78

0.18–3.28

T3, 0.2<LNR≤0.5

598

T3, N0

0.91

0.22–3.74

T3, LNR>0.5

492

T3, N0

1.00

0.25–4.07

T4, LNR≤0.2

143

T4, N0

0.71

0.16–3.22

T4, 0.2<LNR≤0.5

263

T4, N0

0.98

0.23–4.16

T4, LNR>0.5

261

T4, N0

0.97

0.23–4.09

T1T2

T3

T4

Author Manuscript

T: Tumor status; N: Node status; LNR: Lymph Node Ratio
Adjusted for age, sex, marital status, primary tumor site

Author Manuscript
Author Manuscript
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